Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Literature DB >> 28751764

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson, M Friedrich.

Abstract

This corrects the article DOI: 10.1038/leu.2016.388.

Entities: Disease

Year: 2017 PMID： 28751764 DOI： 10.1038/leu.2017.219

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

18 in total

1. CD8⁺ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors: Jillian Rosenberg; Jun Huang
Journal: Curr Opin Chem Eng Date: 2017-12-14 Impact factor: 5.163

Review 2. Novel Agents in Multiple Myeloma.

Authors: Raphaël Szalat; Nikhil C Munshi
Journal: Cancer J Date: 2019 Jan/Feb Impact factor: 3.360

Review 3. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.

Authors: Kitsada Wudhikarn; Beatriz Wills; Alexander M Lesokhin
Journal: Best Pract Res Clin Haematol Date: 2020-01-11 Impact factor: 3.020

Review 4. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors: Z Wu; N V Cheung
Journal: Pharmacol Ther Date: 2017-08-20 Impact factor: 12.310

5. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

Authors: Lydia Lee; Benjamin Draper; Neil Chaplin; Brian Philip; Melody Chin; Daria Galas-Filipowicz; Shimobi Onuoha; Simon Thomas; Vania Baldan; Reyisa Bughda; Paul Maciocia; Eva Kokalaki; Margarida P Neves; Dominic Patel; Manuel Rodriguez-Justo; James Francis; Kwee Yong; Martin Pule
Journal: Blood Date: 2017-12-28 Impact factor: 22.113

6. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

Authors: David J DiLillo; Kara Olson; Katja Mohrs; Thomas Craig Meagher; Kevin Bray; Olga Sineshchekova; Thomas Startz; Jessica Kuhnert; Marc W Retter; Stephen Godin; Prachi Sharma; Frank Delfino; John Lin; Eric Smith; Gavin Thurston; Jessica R Kirshner
Journal: Blood Adv Date: 2021-03-09

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

1. CD8⁺ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Review 2. Novel Agents in Multiple Myeloma.

Review 3. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.

Review 4. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

5. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

6. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

Review 7. Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Review 8. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.

Review 9. What is new in the treatment of Waldenstrom macroglobulinemia?

Review 10. Redirecting T cells to hematological malignancies with bispecific antibodies.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

1. CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Review 2. Novel Agents in Multiple Myeloma.

Review 3. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.

Review 4. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

5. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

6. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.

Review 7. Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Review 8. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.

Review 9. What is new in the treatment of Waldenstrom macroglobulinemia?

Review 10. Redirecting T cells to hematological malignancies with bispecific antibodies.

1. CD8⁺ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.